Talha Badar: Salvage therapy for relapse APL and outcome
Talha Badar, Hematologist/Oncologist at Mayo Clinic in Jacksonville, Florida, shared a post on X:
“Weekend review
Outcome of relapsed APL
Generally, with ATO+ATRA induction CR up 90%, long-term OS 70-80%
Relapses are less common, prior ATO may led to resistance(Zhu NEJM 2014), no clear consensus on auto vs allo-HCT
Brief salvage therapy for relapse APL and outcome
61 pts, Prior Rx ATRA (90%) and ATO (15%); 51% received ATO+ATRA combination, CR rates was 92%, medain OS was 32 vs 164 months with ATRA+ATO salvage.
No additional survival with auto or allo-HCT in pts who Rx with ATRA+ATO
Sasaki et al. CLML 2024
In another study of 52 pts for Korea, 41 received Rx (30 ATO, 11 conventional Rx).
Outcomes were better with ATO salvage therapy with no additional benefit of allo-HCT in improving survival.
Study from India on 67 relapse APL, who were Rx, ~ 29% had CNS relapses. All pts Rx upfront ATO
ATO+ATRA based Rx, 94% achieved molecular remission
4.5% died during re-induction
55% auto-SCT
5 yrs OS 73.6%; 90% with auto and 59% without
Another study on 71 pts from East Asia with long follow up of 94 months.
20% had CNS relapse
Salvage therapy was ATRA+ATO+Ida, pt with CNS disease received IT chemo.
SCT was not done in CR2. 10 yrs LFS was 56.8%.
Italian study on 22 Relapse APL pts, Rx with ATRA+ATO, 91% achieved molecular CR.
One each had auto and allo-HCT.
4 yrs DFS and OS: 74% and 85
Summary Slide!
Source: Talha Badar/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023